Would you proceed to anthracycline based neoadjuvant regimen for locally advanced triple negative breast cancer without clinical response to neoadjuvant paclitaxel or proceed to surgery?

Topics: Breast Cancer • Medical Oncology • Triple negative

BRCA status unknown currently

Answer from: Medical Oncologist at Academic Institution

While a lack of response to paclitaxel (don't you now wish that you had added carboplatin?) is concerning and could indicate that the patient has a type of TNBC that responds poorly to chemotherapy, such as AR+, the patient may respond to a different chemo regimen and thus you should proceed to trea...

Comments

Medical Oncologist at Duke University Medical Center
I agree with @William M. Sikov's response and...

Medical Oncologist at Warren Alpert Medical School of Brown University
I agree with @Gretchen G. Kimmick - would only swi...

Medical Oncologist at RPCI Onc, PC
Few options to consider. Proceed with anthracyclin...

Answer from: Medical Oncologist at Community Practice

Couldn’t agree more with the previous messages. For a drug-resistant TNBC in the neoadjuvant setting, we would continue neoadjuvant therapy unless there is a clear progression of the disease in the breast/nodes or development of metastasis. However, based on the current data, those with low pC...

Related Questions